profit from every $100 of sales.
$0$100
Bioceres Crop Solutions
$0.21-5.41% today
-87.7% in 1 year
1-year low $0.201-year high $1.72
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bioceres Crop Solutions sold, what it kept, and what it did with the cash.
Sales went from $328 million in 2022 to $333 million in 2025, with -$55.4 million of profit last year.
SalesProfit
Bioceres Crop Solutions handed back 3% of the cash it generated last year.
Buybacks $926,899
Free cash flow 2025$35M
Bought back its own shares$926,899
Paid as dividends$0
Cash vs. debt$33M vs. $277M
Bioceres Crop Solutions vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bioceres Crop Solutions | No profit yet | ||
 Nutrien | 14.9× · Cheap | ||
 CF Industries Holdings | 12.6× · Cheap | ||
 Industries Qatar Q.P.S.C. | 14.8× · Cheap | ||
 Qinghai Salt Lake Industry Co.,Ltd | 13.6× · Cheap |
AI analysis
An AI analyst reads Bioceres Crop Solutions's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 328 | 419 | 465 | 333 | |
| 125 | 179 | 182 | 128 | |
| 44 | 53 | 44 | -1 | |
| 38 | 60 | 56 | -10 | |
| -7 | 19 | 4 | -55 | |
| -0.17 | 0.30 | 0.05 | -0.83 | |
| 38.0% | 42.6% | 39.2% | 38.4% | |
| 13.5% | 12.7% | 9.5% | -0.2% | |
| -2.2% | 4.5% | 0.9% | -16.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 518 | 818 | 853 | 764 |
| Cash | 33 | 48 | 44 | 33 |
| Total debt | 170 | 257 | 271 | 277 |
| Total liabilities | 360 | 488 | 501 | 468 |
| 128 | 299 | 315 | 263 | |
| 42 | 63 | 63 | 63 | |
| 7.7% | 5.7% | 4.7% | -4.7% | |
| -5.6% | 6.3% | 1.4% | -21.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -18 | 3 | 42 | 50 | |
| 9 | 23 | 23 | 15 | |
| -27 | -20 | 19 | 35 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| 0 | 3 | 1 | 1 | |
| 1 | 3 | 14 | 4 |
Valuation
- –
- –
- –
- 0.4×
- 0.0×
- 0.4×
- –
- 263.4%
- -413.5%
- 0.0%
Profitability
- 38.4%
- -0.2%
- -16.6%
- 4.2%
- 0.2%
- -2.2%
- -105.5%
- -42.1%
- 0.3%
- 4.1%
Growth
- +0.5%
- –
- +86.4%
- –
- +12.7%
Financial health
- –
- 3.25
- 42.7%
- 0.0×
- 0.90
- 0.69
- 0.51
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 990
Bottom 9%of 950
Bottom 37%of 929
What analysts expect
- Average price target
- $2.00
- Range
- $2.00 – $2.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.16 | -0.05 | −220.0% |
| Mar 13, 2026 | -0.08 | 0.07 | −214.3% |
| Nov 12, 2025 | -0.12 | -0.04 | −200.0% |
| May 21, 2025 | -0.02 | -0.10 | +80.0% |
| Feb 11, 2025 | 0.01 | 0.14 | −92.9% |
| Nov 11, 2024 | -0.09 | -0.01 | −800.0% |
| Sep 9, 2024 | -0.03 | 0.20 | −115.0% |
| May 13, 2024 | 0.14 | 0.16 | −12.5% |
News
Bioceres reports Q1 resultsSeeking Alpha · Nov 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
39No pass
Philip Fisher
18No pass
Peter Lynch
1No pass
Joel Greenblatt
0No pass
Charlie Munger
9No pass
Terry Smith
7No pass
Questions about Bioceres Crop Solutions
Is Bioceres Crop Solutions a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bioceres Crop Solutions AI analysis
What does Bioceres Crop Solutions do?
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. It is in Agricultural Inputs.
Does Bioceres Crop Solutions pay a dividend?
No. Bioceres Crop Solutions does not pay a dividend at the moment; in 2025 it returned $926,899 to shareholders by buying back its own shares.
Is Bioceres Crop Solutions stock halal?
No. Bioceres Crop Solutions does not pass our halal screen: its debt is 2,064% of its market value, at or above the 33% limit. How we check
How has Bioceres Crop Solutions stock done over the past year?
Down 87.7% over the past twelve months, to $0.21. It traded between $0.20 and $1.72 and is 87.8% below its high.
Who are Bioceres Crop Solutions's competitors?
The largest listed companies in the same industry are Nutrien, CF Industries Holdings, Industries Qatar Q.P.S.C. and Qinghai Salt Lake Industry Co.,Ltd. The peers table on this page compares their profit, growth and price with Bioceres Crop Solutions's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.